Posted on

Nova Mentis receives approval for autism clinical study

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Are psychedelics the future of autism treatment? Nova Mentis Life Sciences Corp. (NOVA) received Canadian approval for a new study on autism, which will be the first step in bringing psilocybin treatment to autistic patients. Researchers will observe 200 patients with autism spectrum disorder (ASD) or fragile x syndrome (FXS) to establish baseline biomarkers that can be used to measure psilocybin treatment responses in a later study. NOVA will monitor the gut microbiome, immune response, and serotonin activity in patients, as these factors influence behavioural symptoms.

PDF of article

Posted on

PsyBio Therapeutics (PSYB) begins manufacturing in France

PsyBio Therapeutics Initiates European Manufacturing of Proprietary Biosynthetic Psychedelic Compounds including Psilocybin with France-based Biose Industrie

PsyBio Therapeutics Corp. (PSYB), a Florida-based biotech company, began manufacturing their biosynthetic psilocybin formulations for further testing at a certified facility in France. PsyBio partnered with Biose Industrie to support their European expansion, a company with over 70 years of experience in commercializing pharmaceuticals with live bacterial strains. “Our partnership with Biose will further our research and development goals and demonstrate our commitment to the development of globally-tested and approved therapeutics,” PsyBio’s Chief Medical Officer stated.

PDF of article

Posted on

Revive Therapeutics brings psychedelic treatment and education to the Caribbean

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

Revive Therapeutics Ltd. will partner with the University of Health Sciences Antigua (UHSA) to open a psychedelic treatment center in the Caribbean. The center will treat substance abuse disorders and other mental health conditions using Revive’s psilocybin oral thin film patch. As part of the agreement, UHSA will establish a Master’s in Psychedelic Medicine program for students wanting to learn more about the field.

PDF of article

Posted on

Diamond Therapeutics begins study on very low doses of psilocybin

Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial

While there have been few studies on microdosing psilocybin, Diamond Therapeutics Inc.’s preclinical research suggests that very low, non-hallucinogenic doses of psilocybin have potential for treating disorders like anxiety and depression. Diamond is now partnering with BioPharma Services Inc. to expand on this research in a new phase 1 clinical trial, which will explore a range of very low doses of psilocybin.

PDF of article

Posted on

Atai Life Sciences (ATAI) lists on NASDAQ, becomes third psilocybin company to list on major US stock exchange

atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Atai Life Sciences (ATAI), a German biopharmaceutical company studying psilocybin treatment, began trading on the NASDAQ at $15 per share. Gross proceeds are expected to be $225 million. ATAI is the third psilocybin-focused company to go public on a major US stock exchange, following MindMed and Compass Pathways.

PDF of article

Posted on

Mydecine launches new AI drug discovery program

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group (MYCO) partnered with the University of Alberta to launch a new AI drug discovery program that will make their research more efficient. The in-silico program uses machine learning and artificial intelligence to “rapidly screen hundreds of thousands of new molecules without the need to produce them, allowing Mydecine to focus on the strongest potential therapeutics”.

PDF of article

Posted on

Field Trip’s psychedelic compound produces a two to four hour trip, half the duration of psilocybin

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Field Trip Health Ltd. (FTRP) has completed the initial drug metabolism and pharmacokinetic (DMPK) studies for its psychedelic compound FT-104. The studies found that the psychedelic effects from FT-104 last for just two to four hours, about half the time as a psilocybin trip, making it more “clinically efficient and accessible”. Field Trip is now looking to apply for Phase 1 human trials after confirming that the compound is easy to synthesize and has low risk for addiction.

PDF of article

Posted on

Mindset’s COPE program provides benchmark data to measure success of new psychedelic drug formulations

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

The first psychedelic benchmark data was made available through the Cooperative Psychedelic Evaluation Platform (COPE), a program started by Mindset Pharma Inc. and InterVivo Solutions in March. The benchmark data is used to measure the success of new psychedelic drug formulations and “will undoubtedly help the value assessment of newer psychedelics in development”, according to Chief Scientific Officer of InterVivo. The data on psilocybin suggests that “the clinical exposure levels reported in humans correlates well to exposure and efficacy measures observed in mice”.

PDF of article

Posted on

Core One Labs awaits patent for cost-effective biosynthetic psilocybin production system

Core One Labs’ Biosynthesized Psilocybin Provisional Patent Imminent

Vocan Biotechnologies Inc., a subsidiary of Core One Labs Inc. (COOL) is days away from receiving a patent for its biosynthetic psilocybin production system, which is more efficient and significantly cheaper than conventional methods of extracting psilocybin. The proprietary system aims to produce a reliable product that is consistent in quality and concentration while remaining comparable to naturally occurring psilocybin. Core One believes that there is a wide appeal for biosynthetic production as the psychedelics market grows, as “the need for a steady and consistent supply chain will also increase”.

PDF of article

Posted on

Mydecine discovered more than 40 new compounds with medical potential in various mushroom species

Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Mydecine Innovations Group discovered over 40 new compounds with medical potential when screening 25 mushroom species. Mydecine’s senior scientist, Duff Sloley, said that chemical components in many species, especially the poisonous ones, have not been researched. Sloley explained that the compounds are very complex because they’ve evolved to protect the mushrooms from predators. “Since these compounds are evolved to affect biological systems and aspects of metabolic pathways, they stand a higher chance of proving to be useful pharmaceuticals”.

PDF of article